Safety, tolerability and efficacy of 212Pb-DOTAMTATE as a targeted alpha therapy for subjects with unresectable or metastatic somatostatin receptor-expressing gastroenteropancreatic neuroendocrine tumors (SSTR+ GEP-NETs): A phase 2 study

Authors

Jonathan R. Strosberg, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL
Shagufta Naqvi, Excel Diagnostics Nuclear Oncology Center, Houston, TX
Allen Lee Cohn, Rocky Mountain Cancer Centers, Denver, CO
Ebrahim S . Delpassand, RadioMedix Inc., Houston, TX
Volker Jean Wagner, Orano Med SAS, Chatillon, France
Izabela Tworowska, RadioMedix Inc., Houston, TX
Julien Torgue, Orano Med LLC, Plano, TX
Rachel Woloski, Orano Med LLC, Plano, TX
Allison Manuel, Orano Med LLC, Plano, TX
Mary Alice Maluccio, LSU Health Sciences Center - New OrleansFollow

Document Type

Conference Proceeding

Publication Date

5-29-2024

Publication Title

Journal of Clinical Oncology

Abstract

Annual Meeting of the American Society of Clinical Oncology, ASCO 2024, May 31-June 4, 2024, Chicago, IL

Volume

42

Issue

16, Supplement

Comments

Abstract 4020

Rights

© 2024, Wolters Kluwer Health

Recommended Citation

Strosberg, Jonathan R.; Naqvi, Shagufta; Cohn, Allen Lee; Delpassand, Ebrahim S .; Wagner, Volker Jean; Tworowska, Izabela; Torgue, Julien; Woloski, Rachel; Manuel, Allison; and Maluccio, Mary Alice, "Safety, tolerability and efficacy of 212Pb-DOTAMTATE as a targeted alpha therapy for subjects with unresectable or metastatic somatostatin receptor-expressing gastroenteropancreatic neuroendocrine tumors (SSTR+ GEP-NETs): A phase 2 study" (2024). School of Medicine Faculty Publications. 4131.
https://digitalscholar.lsuhsc.edu/som_facpubs/4131
10.1200/JCO.2024.42.16_suppl.4020